Date published: 2025-10-21

1-800-457-3801

SCBT Portrait Logo
Seach Input

PARP Inhibitor IX, EB-47 (CAS 366454-36-6)

0.0(0)
Write a reviewAsk a question

See product citations (2)

Application:
PARP Inhibitor IX, EB-47 is an isoindolinone compound that inhibits PARP-1
CAS Number:
366454-36-6
Purity:
≥95%
Molecular Weight:
646.5
Molecular Formula:
C24H27N9O62HCl•2H2O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

PARP Inhibitor IX, EB-47 is a cell-permeable, adenosine-substituted, isoindolinone compound that acts as a strong inhibitor of poly(ADP-ribose) polymerase 1 (PARP-1). In addition, it is a dual site inhibitor of tankyrase 2 (TNKS2 IC50 = 45 nM) and also inhibits tankyrase 1 (TNKS1) and PARP10 with IC50s of 410 and 1,179 nM, respectively. PARP Inhibitor IX, EB-47 may act to offer cytoprotective effects against oxidative damage in cells and models of reperfusion injury and inflammation.


PARP Inhibitor IX, EB-47 (CAS 366454-36-6) References

  1. ATR signaling mediates an S-phase checkpoint after inhibition of poly(ADP-ribose) polymerase activity.  |  Horton, JK., et al. 2007. DNA Repair (Amst). 6: 742-50. PMID: 17292679
  2. A colorimetric substrate for poly(ADP-ribose) polymerase-1, VPARP, and tankyrase-1.  |  Nottbohm, AC., et al. 2007. Angew Chem Int Ed Engl. 46: 2066-9. PMID: 17299820
  3. Inhibition of matrix metalloproteinase-2 by PARP inhibitors.  |  Nicolescu, AC., et al. 2009. Biochem Biophys Res Commun. 387: 646-50. PMID: 19619515
  4. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation.  |  Mangerich, A. and Bürkle, A. 2011. Int J Cancer. 128: 251-65. PMID: 20853319
  5. Inhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasite.  |  Vilchez Larrea, SC., et al. 2012. PLoS One. 7: e46063. PMID: 23049934
  6. Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors.  |  Haikarainen, T., et al. 2014. ACS Med Chem Lett. 5: 18-22. PMID: 24900770
  7. Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.  |  Qiu, W., et al. 2014. Acta Crystallogr D Biol Crystallogr. 70: 2740-53. PMID: 25286857
  8. Craniula: A cranial window technique for prolonged imaging of brain surface vasculature with simultaneous adjacent intracerebral injection.  |  Zuluaga-Ramirez, V., et al. 2015. Fluids Barriers CNS. 12: 24. PMID: 26507826
  9. HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation.  |  Suskiewicz, MJ., et al. 2020. Nature. 579: 598-602. PMID: 32028527
  10. Recent advancements in PARP inhibitors-based targeted cancer therapy.  |  Zhou, P., et al. 2020. Precis Clin Med. 3: 187-201. PMID: 32983586
  11. Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition.  |  Ogden, TEH., et al. 2021. Nucleic Acids Res. 49: 2266-2288. PMID: 33511412
  12. PARP1: Structural insights and pharmacological targets for inhibition.  |  Spiegel, JO., et al. 2021. DNA Repair (Amst). 103: 103125. PMID: 33940558
  13. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.  |  van Beek, L., et al. 2021. Int J Mol Sci. 22: PMID: 34066057
  14. A two-step mechanism governing PARP1-DNA retention by PARP inhibitors.  |  Xue, H., et al. 2022. Sci Adv. 8: eabq0414. PMID: 36070389

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

PARP Inhibitor IX, EB-47, 1 mg

sc-222125
1 mg
$178.00